Zynex Investors: Can You Lead the Class Action Lawsuit? Here’s What You Need to Know

Investors in Zynex, Inc. (NASDAQ: ZYXI) who suffered losses may have a critical opportunity to shape the outcome of a high-stakes securities fraud lawsuit. With a lead plaintiff deadline of May 19, 2025, eligible investors must act swiftly to assert their rights—or risk missing a chance to influence a case that could recover billions.

The Allegations: A Scheme of Over-Supplying and Deception

The lawsuit Tuncel v. Zynex, Inc. (25-cv-00913) accuses the medical device company of systematically inflating revenue by over-supplying products to patients. Key claims include:
- Excessive shipments: Zynex allegedly sent medical devices like electrodes and batteries in quantities far exceeding patient needs.
- Fraudulent billing: The company reportedly billed insurers—including the U.S. military’s Tricare program—for unnecessary supplies, artificially boosting revenue.
- Misleading disclosures: Zynex is accused of downplaying risks, such as the likelihood of insurers suspending payments or penalizing the company for unethical billing practices.

Key Events That Unraveled the Fraud

Two pivotal moments triggered the lawsuit and caused severe stock collapses:
1. June 4, 2024: A STAT report exposed Zynex’s “oversupplying scheme,” leading to a 5% drop in its stock.
2. March 11, 2025: Zynex announced a revenue shortfall and revealed that Tricare had suspended payments over billing disputes. This news sent shares plummeting 51% in a single day.

The chart would show a steady rise during the Class Period, followed by sharp declines post-STAT report and the March 2025 announcement.

The Legal Landscape: A Race Against the Clock

The case is still in its early stages, with no class yet certified. However, investors who purchased ZYXI shares between March 13, 2023, and March 11, 2025, are eligible to:
- Join the class passively for potential recovery.
- Become lead plaintiff by filing a motion by May 19, 2025.

Lead plaintiffs play a pivotal role, working closely with attorneys to guide the litigation. While the position comes with responsibility, it also offers greater influence over case strategy.

Why This Case Matters—and How to Act

Zynex’s stock has been a rollercoaster, but the lawsuit’s success hinges on proving the company’s material misstatements. If the plaintiffs prevail, recovery could be substantial, especially given Zynex’s valuation and the severity of the alleged fraud.

This comparison would underscore the dramatic impact of the revelations, with March 2025’s 51% drop being particularly damning.

The Path Forward for Investors

1. Contact a law firm: Firms like Glancy Prongay & Murray LLP and Robbins Geller Rudman & Dowd LLP specialize in securities fraud, with Robbins Geller alone securing over $2.5 billion in recoveries in 2024.
2. Submit a claim: Even if you don’t seek lead plaintiff status, registering ensures you’re eligible for any settlement or judgment.
3. Understand the risks: While the case is strong, outcomes depend on proving Zynex’s intent and the causal link between its omissions and investor losses.

Conclusion: A Crucial Moment for ZYXI Investors

Zynex’s alleged misconduct—over-supplying devices, inflating revenue, and hiding risks—has already cost investors billions. With its stock down 51% in a single day, the company’s credibility is shattered. The May 19 deadline is not just a technicality; it’s a lifeline for those seeking accountability.

The data is clear: the 51% plunge on March 11, 2025, underscores the market’s swift judgment of Zynex’s actions. Law firms’ past recoveries—like Robbins Geller’s $2.5 billion—signal that investors can push for meaningful compensation.

For those holding ZYXI shares during the Class Period, the choice is stark: act now to protect your rights, or risk losing the chance to recover losses. The clock is ticking—investors must move decisively to ensure justice.